STAT reports that incoming Democratic chairs of major committees are preparing to investigate most-favoured-nation (MFN) drug pricing agreements made between drugmakers and the Trump administration. The move signals possible scrutiny of past pricing policies and their impact on the pharmaceutical sector.
This development matters for pharma executives and healthcare leaders as it may lead to regulatory reviews or changes in how drug prices are set in the US. Companies could face new compliance demands or shifts in reimbursement models if the investigation gains traction.
